| Understanding breast cancer risk‐where do we stand in 2005? RG Dumitrescu, I Cotarla Journal of cellular and molecular medicine 9 (1), 208-221, 2005 | 883 | 2005 |
| Update of incidence, prevalence, survival, and initial treatment in patients with non–small cell lung cancer in the US AK Ganti, AB Klein, I Cotarla, B Seal, E Chou JAMA oncology 7 (12), 1824-1832, 2021 | 317 | 2021 |
| Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers I Cotarla, S Ren, Y Zhang, E Gehan, B Singh, PA Furth International journal of cancer 108 (5), 665-671, 2004 | 179 | 2004 |
| A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies JF Deeken, R Slack, GJ Weiss, RK Ramanathan, MJ Pishvaian, J Hwang, ... Cancer chemotherapy and pharmacology 71, 627-633, 2013 | 84 | 2013 |
| A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies MJ Pishvaian, JL Marshall, AJ Wagner, JJ Hwang, S Malik, I Cotarla, ... Cancer 118 (21), 5403-5413, 2012 | 74 | 2012 |
| Conditional over-expression of estrogen receptor alpha in a transgenic mouse model KS Hruska, MT Tilli, S Ren, I Cotarla, T Kwong, M Li, JD Fondell, JA Hewitt, ... Transgenic research 11, 361-372, 2002 | 35 | 2002 |
| Comparison of mouse mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound MT Tilli, AR Parrish, I Cotarla, LP Jones, MD Johnson, PA Furth BMC cancer 8, 1-15, 2008 | 22 | 2008 |
| A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy MJ Pishvaian, R Slack, EY Koh, JH Beumer, ML Hartley, I Cotarla, ... Cancer chemotherapy and pharmacology 70, 843-853, 2012 | 21 | 2012 |
| A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion MJ Pishvaian, JL Marshall, JJ Hwang, S Malik, AR He, JF Deeken, ... Journal of Clinical Oncology 27 (15_suppl), 3581-3581, 2009 | 20 | 2009 |
| Treatment decision drivers in stage III non–small-cell lung cancer: outcomes of a web-based survey of oncologists in the United States I Cotarla, ML Boron, SL Cullen, DS Spinner, EC Faulkner, MC Carroll, ... JCO oncology practice 16 (10), e1232-e1242, 2020 | 13 | 2020 |
| P3-112: Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors S Malik, J Hwang, I Cotarla, T Sullivan, R Karr, J Marshall Journal of Thoracic Oncology 2 (8), S726-S727, 2007 | 10 | 2007 |
| Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies. MJ Pishvaian, I Cotarla, AJ Wagner, JF Deeken, AR He, JJ Hwang, ... Journal of Clinical Oncology 28 (15_suppl), 2526-2526, 2010 | 9 | 2010 |
| Patient and caregiver preferences for first-line treatments of metastatic non-small cell lung cancer: a discrete choice experiment C Yong, MJ Cambron-Mellott, B Seal, O Will, MC Maculaitis, K Clapp, ... Patient preference and adherence, 123-135, 2022 | 3 | 2022 |
| Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a US community oncology … DM Waterhouse, C Yong, NJ Robert, KM Aguilar, J Ndukum, Y Xie, ... Journal of Clinical Oncology 39 (28_suppl), 295-295, 2021 | 2 | 2021 |
| Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting D Waterhouse, C Yong, A Frankart, L Brannman, T Mulrooney, N Robert, ... Future Oncology 19 (28), 1905-1916, 2023 | 1 | 2023 |
| Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non–small cell lung cancer treated at Veterans Health Administration facilities. A Moore, Z Nooruddin, KR Reveles, P Datta, L Brannman, I Cotarla, ... Journal of Clinical Oncology 40 (16_suppl), 8526-8526, 2022 | 1 | 2022 |
| OFP01. 09 Economic Burden of Metastatic Non-Small Cell Lung Cancer (mNSCLC) in a Large United States (US) Claims Database E Chou, AK Ganti, K Katranji, I Cotarla, C Sharma, B Miao, M Garg, B Seal Journal of Thoracic Oncology 16 (1), S11-S12, 2021 | 1 | 2021 |
| PP01. 116 Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in US patients with unresectable stage III NSCLC following concurrent chemoradiation R Haque, E McGary, M Yang, R Liu, JM Suga, LH Chen, Z Zhu, ... Journal of Thoracic Oncology 19 (7), e50, 2024 | | 2024 |
| A Prospective, Multi-Institutional Digital Health Pilot Study to Detect Pneumonitis Early in Patients with Stage III NSCLC on durvalumab Monitored Remotely: Findings from the … I Cotarla, AN Saltos, TD Peikert, B Tannenwald, K Hsieh, OC Irabor, ... International Journal of Radiation Oncology, Biology, Physics 118 (1), e8-e9, 2024 | | 2024 |
| Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study AM Moore, Z Nooruddin, KR Reveles, P Datta, JM Whitehead, K Franklin, ... Current Oncology 30 (9), 8411-8423, 2023 | | 2023 |
